Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Clarifying the concept of chronic kidney disease for non-nephrologists.

Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Fernandez-Fernandez B, Martin-Cleary C, Gracia-Iguacel C, Ortiz A.

Clin Kidney J. 2019 Feb 14;12(2):258-261. doi: 10.1093/ckj/sfz007. eCollection 2019 Apr.

2.

Podocyturia: why it may have added value in rare diseases.

Sanchez-Niño MD, Perez-Gomez MV, Valiño-Rivas L, Torra R, Ortiz A.

Clin Kidney J. 2018 Oct 5;12(1):49-52. doi: 10.1093/ckj/sfy081. eCollection 2019 Feb.

PMID:
30863545
3.

Potential Dangers of Serum Urate-Lowering Therapy.

Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M, Ortiz A.

Am J Med. 2019 Apr;132(4):457-467. doi: 10.1016/j.amjmed.2018.12.010. Epub 2019 Jan 3. Review.

PMID:
30611833
4.

Advances in understanding the role of angiotensin-regulated proteins in kidney diseases.

Sanz AB, Ramos AM, Soler MJ, Sanchez-Niño MD, Fernandez-Fernandez B, Perez-Gomez MV, Ortega MR, Alvarez-Llamas G, Ortiz A.

Expert Rev Proteomics. 2018 Nov 9:1-16. doi: 10.1080/14789450.2018.1545577. [Epub ahead of print]

PMID:
30412432
5.

Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development.

Perez-Gomez MV, Martin-Cleary C, Fernandez-Fernandez B, Ortiz A.

Clin Kidney J. 2018 Aug;11(4):491-495. doi: 10.1093/ckj/sfy070. Epub 2018 Jul 31.

6.

Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression.

Castillo-Rodriguez E, Fernandez-Prado R, Esteras R, Perez-Gomez MV, Gracia-Iguacel C, Fernandez-Fernandez B, Kanbay M, Tejedor A, Lazaro A, Ruiz-Ortega M, Gonzalez-Parra E, Sanz AB, Ortiz A, Sanchez-Niño MD.

Toxins (Basel). 2018 Jul 19;10(7). pii: E300. doi: 10.3390/toxins10070300. Review.

7.

Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?

Magalhães P, Pejchinovski M, Markoska K, Banasik M, Klinger M, Švec-Billá D, Rychlík I, Rroji M, Restivo A, Capasso G, Bob F, Schiller A, Ortiz A, Perez-Gomez MV, Cannata P, Sanchez-Niño MD, Naumovic R, Brkovic V, Polenakovic M, Mullen W, Vlahou A, Zürbig P, Pape L, Ferrario F, Denis C, Spasovski G, Mischak H, Schanstra JP.

Sci Rep. 2017 Dec 5;7(1):16915. doi: 10.1038/s41598-017-17083-w.

8.

Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.

Fernandez-Prado R, Esteras R, Perez-Gomez MV, Gracia-Iguacel C, Gonzalez-Parra E, Sanz AB, Ortiz A, Sanchez-Niño MD.

Nutrients. 2017 May 12;9(5). pii: E489. doi: 10.3390/nu9050489. Review.

9.

Circulating CXCL16 in Diabetic Kidney Disease.

Elewa U, Sanchez-Niño MD, Mahillo-Fernández I, Martin-Cleary C, Belen Sanz A, Perez-Gomez MV, Fernandez-Fernandez B, Ortiz A.

Kidney Blood Press Res. 2016;41(5):663-671. Epub 2016 Sep 26.

10.

Targeting inflammation in diabetic kidney disease: early clinical trials.

Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Zheng B, Martín-Cleary C, Ruiz-Ortega M, Ortiz A, Fernandez-Fernandez B.

Expert Opin Investig Drugs. 2016 Sep;25(9):1045-58. doi: 10.1080/13543784.2016.1196184. Epub 2016 Jun 13. Review.

PMID:
27268955
11.

Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes.

Perez-Gomez MV, Gonzalez-Parra E, Ortiz A.

Clin Kidney J. 2015 Oct;8(5):576-9. doi: 10.1093/ckj/sfv088. Epub 2015 Sep 1.

12.

Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.

Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, Ortiz A, Fernandez-Fernandez B.

Ther Adv Drug Saf. 2015 Aug;6(4):166-76. doi: 10.1177/2042098615589905. Review.

13.

Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade.

Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Martín-Cleary C, Ruiz-Ortega M, Egido J, Navarro-González JF, Ortiz A, Fernandez-Fernandez B.

J Clin Med. 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. Review.

14.

Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD.

Rodriguez-Osorio L, Vanessa Perez-Gomez M, Ortiz A.

Kidney Int. 2015 Jul;88(1):194. doi: 10.1038/ki.2015.95. No abstract available.

PMID:
26126094
15.

Modifiable risk factors for increased arterial stiffness in outpatient nephrology.

Elewa U, Fernandez-Fernandez B, Alegre R, Sanchez-Niño MD, Mahillo-Fernández I, Perez-Gomez MV, El-Fishawy H, Belal D, Ortiz A.

PLoS One. 2015 Apr 16;10(4):e0123903. doi: 10.1371/journal.pone.0123903. eCollection 2015.

Supplemental Content

Loading ...
Support Center